A case of stage III c ovarian clear cell carcinoma: The role for predictive biomarkers and targeted therapies

International Journal of Molecular Sciences

Volumn 14, Issue 3, 2013, Pages 6067-6073

  Rahman, Munmun ^a   Nakayama, Kentaro ^a   Ishibashi, Tomoka ^a   Ishikawa, Masako ^a   Rahman, Mohammed Tanjimur ^a   Katagiri, Hiroshi ^a   Katagiri, Atsuko ^a   Iida, Kouji ^a   Kikuchi, Yoshihiro ^b   Miyazaki, Kohji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b Ohki Memorial Kikuchi Cancer Clinic for Women   (Japan)

Author keywords

Biomarkers; mTOR inhibitor; Ovarian clear cell carcinoma; PIK3CA

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; IRINOTECAN; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; SORAFENIB; TEMSIROLIMUS; TUMOR MARKER;

ABDOMINAL HYSTERECTOMY; ADNEXA DISEASE; ADULT; ARID1A GENE; ARTICLE; ASCITES; CANCER STAGING; CASE REPORT; CLEAR CELL CARCINOMA; COLON RESECTION; CYTOREDUCTIVE SURGERY; DEATH; DRUG SUBSTITUTION; DRUG TARGETING; ENDOMETRIOSIS; ERYTHEMA; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; JAPANESE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MESENTERY LYMPH NODE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OMENTECTOMY; OMENTUM; OVARIAN CLEAR CELL CARCINOMA; PATIENT REFERRAL; PERITONEUM METASTASIS; PIK3CA GENE; POSTMENOPAUSE; PREDICTION; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE; TUMOR GENE;

EID: 84875530068     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14036067     Document Type: Article

References (16)

1. Itamochi, H.; Kigawa, J.; Terakawa, N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008, 99, 653-658.
2. Sugiyama, T.; Kamura, T.; Kigawa, J.; Terakawa, N.; Kikuchi, Y.; Kita, T.; Suzuki, M.; Sato, I.; Taguchi, K. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88, 2584-2589.
3. Jones, S.; Wang, T.L.; Shih, I.-M.; Mao, T.L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L.A., Jr.; Vogelstein, B.; et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330, 228-231.
4. Rahman, M.; Nakayama, K.; Rahman, M.T.; Nakayama, N.; Ishikawa, M.; Katagiri, A.; Iida, K.; Nakayama, S.; Otsuki, Y.; Shih, I.-M.; et al. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum. Pathol. 2012, 43, 2197-2206.
5. Uno, K.; Homma, S.; Satoh, T.; Nakanishi, K.; Abe, D.; Matsumoto, K.; Oki, A.; Tsunoda, H.; Yamaguchi, I.; Nagasawa, T.; et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br. J. Cancer 2007, 96, 290-295.
6. Kurman, R.J.; Shih, I.-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm. Hum. Pathol. 2011, 42, 918-931.
7. Lalwani, N.; Prasad, S.R.; Vikram, R.; Shanbhogue, A.K.; Huettner, P.C.; Fasih, N. Histologic, molecular, and cytogenetic features of ovarian cancers: Implications for diagnosis and treatment. Radiographics 2011, 31, 625-646.
8. Han, E.S.; Lin, P.; Wakabayashi, M. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr. Treat. Options Oncol. 2009, 10, 54-66.
9. Markman, M. Antiangiogenic drugs in ovarian cancer. Expert Opin. Pharmacother. 2009, 10, 2269-2277.
10. Behbakht, K.; Sill, M.W.; Darcy, K.M.; Rubin, S.C.; Mannel, R.S.; Waggoner, S.; Schilder, R.J.; Cai, K.Q.; Godwin, A.K.; Alpaugh, R.K. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A gynecologic oncology group study. Gynecol. Oncol. 2011, 123, 19-26.
11. Matsumura, N.; Mandai, M.; Okamoto, T.; Yamaguchi, K.; Yamamura, S.; Oura, T.; Baba, T.; Hamanishi, J.; Kang, H.S.; Matsui, S.; et al. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci. 2010, 101, 2658-2663.
12. Janku, F.; Wheler, J.J.; Westin, S.N.; Moulder, S.L.; Naing, A.; Tsimberidou, A.M.; Fu, S.; Falchook, G.S.; Hong, D.S.; Garrido-Laguna, I.; et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 2012, 30, 777-782.
13. Takano, M.; Kikuchi, Y.; Kudoh, K.; Goto, T.; Furuya, K.; Kikuchi, K.; Kita, T.; Fujiwara, K.; Shiozawa, T.; Aoki, D. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases. Int. J. Clin. Oncol. 2011, 16, 605-609.
14. Shoji, K.; Oda, K.; Kashiyama, T.; Ikeda, Y.; Nakagawa, S.; Sone, K.; Miyamoto, Y.; Hiraike, H.; Tanikawa, M.; Miyasaka, A.; et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 2012, 7, e37431.
15. Katagiri, A.; Nakayama, K.; Rahman, M.T.; Rahman, M.; Katagiri, H.; Nakayama, N.; Ishikawa, M.; Ishibashi, T.; Iida, K.; Kobayashi, H.; et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod. Pathol. 2012, 25, 282-288.
16. Yamaguchi, K.; Mandai, M.; Oura, T.; Matsumura, N.; Hamanishi, J.; Baba, T.; Matsui, S.; Murphy, S.K.; Konishi, I. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010, 29, 1741-1752.